Diabetes Mellitus, Diabetic Retinopathy, Hormones
Conditions
Keywords
Diabetic retinopathy, GPER-1, oestradiol, progesterone, TSH, oxidative stress, neuronal damage.
Brief summary
Observational, comparative, cross-sectional study
Detailed description
This study was conducted on G protein-mediated estrogen receptor 1 (GPER-1), which is thought to be effective in preventing the development of diabetic retinopathy (DR). There are studies proving that GPER-1 prevents neuroprotective effects and vascular pathology in many tissues. In the study, serum GPER-1 and oxidative stress biomarker levels were compared in diabetic patients and healthy control groups. GPER-1 was found to be significantly increased in diabetic patients. In addition, a positive correlation was found with oxidant markers. This may lead to new treatment models in the future.
Interventions
DIAGNOSTIC_TESTThe effect of GPER-1 on the formation of diabetic retinopathy
Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
Sponsors
Kahramanmaras Sutcu Imam University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* 40 individuals were required to have Proliferative Diabetic Retinopathy (PDR); * 40 were required to have Non-PDR; * 40 were required to be healthy, without any systemic disease.
Exclusion criteria
* Glaucoma, * Ocular trauma sequelae, * Pathological myopia, * Non-diabetic retinopathy, * A history of previous ocular surgery, * Endocrine disorders (e.g.,thyroidopathy, adrenal gland disorders, pituitary pathologies), * Opacities interfering with fundus examination (e.g., corneal opacity, lens opacity, vitreous cloudiness other than diabetic haemorrhage).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| G receptor-mediated protein-1 (GPER-1) | Baseline | Variation of GPER-1 during the development of diabetic retinopathy |
| Oxidative/antioxidative stress markers (malondialdehyde [MDA]) | Baseline | Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy |
| Oxidative/antioxidative stress markers (catalase [CAT]) | Baseline | Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy |
| Oxidative/antioxidative stress markers (superoxide dismutase [SOD] | Baseline | Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy |
| Thyroid stimulating hormone (TSH) | Baseline | Variation of TSH during the development of diabetic retinopathy |
| Progesterone | Baseline | Variation of progeterone during the development of diabetic retinopathy |
| oestradiol | Baseline | Variation of oestradiol during the development of diabetic retinopathy |
Countries
Turkey (Türkiye)
Outcome results
None listed